OpenGamma, a specialist in market structure risk management solutions, has enhanced its multi-CCP margining solution to support Eurex ETD, OTC, and Cross Margining.
The Eurex Clearing Prisma Margin Estimator (PME), which was announced this week, is based on the OpenGamma Margining Eurex Clearing Module.
Better measurement and management of CCP exposures and associated costs is fast becoming a critical aspect of risk and capital management in the OTC derivatives market. The optimisation of those costs through various mechanisms, whether through active collateral substitutions or capitalising on available cross-margining benefits, is an important next step for the industry in a balance sheet-constrained world.
“We have been seeing increasing demand for better analytical capabilities across different CCP risk regimes due to regulatory pressures on balance sheets,” says Mas Nakachi (pictured), CEO of OpenGamma. “This is the latest example of how our software helps clients optimise their capital across all clearing venues and lines of business.”
“OpenGamma’s excellent platform provides both the transparency and flexibility for an easy-to-integrate service for fast margin analysis. The OpenGamma Eurex Clearing Module will help our clients to see the savings of our advanced margin methodology and thus the benefits of chosing Eurex Clearing,” explained Thomas Laux, Chief Risk Officer of Eurex Clearing.

OpenGamma is a new breed of financial technology firm whose guiding principle is to work with the derivatives industry in an open and collaborative manner to develop innovative technologies that address its increasingly complex needs.
